A set of 152 NPC compounds were identified as potential hCAR antagonists through the primary screening, of which 32 compounds had an efficacy >100%, 75 with efficacy between 75% and 100%, and 45 at the efficacy of 40% to 75% in comparison to PK11195 (Fig. 4B). Here, CXADR is linked to nasopharyngeal carcinoma.